Insulet (PODD)
(Delayed Data from NSDQ)
$194.38 USD
-2.38 (-1.21%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $194.51 +0.13 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Insulet Corporation [PODD]
Reports for Purchase
Showing records 261 - 280 ( 344 total )
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 4,000+ pump users (2007 - present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Insulet-Amgen 5 Year Deal for OmniPod A Strong Positive
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Inline Q3 on revs, EPS below expectations, next-gen OmniPod transition goes on
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Thank Goodness the Transition is Behind them; Full Speed Ahead
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Insulet Adds Medical Director With Artificial Pancreas Work and Other Extensive Expertise
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Initiating Coverage with a Buy Rating and $44 price target.
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Q2 inline, next gen OmniPod generating new interest, transitioning well
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
New pods appear well received, raising target to $33, lowering to HOLD on valuation
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Q1 inline, guidance maintained, reiterating BUY, raising PT to $28.00
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 3,200+ pump users (2007 - present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Q4 results inline, 2013 OmniPod guidance midpoint ahead of expectations
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 2,900+ pump users
Provider: FELTL & COMPANY
Analyst: HAYNOR B